We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

142 hedge funds and large institutions have $628M invested in Kiniksa Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 39 increasing their positions, 57 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $7.55M | Put options by funds: $4.91M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

6% more funds holding

Funds holding: 134 → 142 (+8)

2.21% more ownership

Funds ownership: 98.97% → 101.18% (+2.2%)

4% more capital invested

Capital invested by funds: $606M → $628M (+$22.6M)

32% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 57

Holders
142
Holders Change
+8
Holders Change %
+5.97%
% of All Funds
2.07%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
29
Increased
39
Reduced
57
Closed
20
Calls
$7.55M
Puts
$4.91M
Net Calls
+$2.64M
Net Calls Change
+$2.03M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$27.9M
2
FFM
Fairmount Funds Management
Pennsylvania
+$6.72M
3
Walleye Capital
Walleye Capital
New York
+$5.38M
4
GIM
Granahan Investment Management
Massachusetts
+$3.09M
5
DCM
Driehaus Capital Management
Illinois
+$2.6M

Top Sellers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
-$12.1M
2
State Street
State Street
Massachusetts
-$3.54M
3
Invesco
Invesco
Georgia
-$3.29M
4
Ameriprise
Ameriprise
Minnesota
-$2.98M
5
Millennium Management
Millennium Management
New York
-$2.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
AQR Capital Management
26
AQR Capital Management
Connecticut
$4M -$1.57M -95,533 -30%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
27
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$3.99M -$247K -15,000 -6%
SSA
28
Schonfeld Strategic Advisors
New York
$3.97M +$295K +17,951 +9%
Hudson Bay Capital Management
29
Hudson Bay Capital Management
Connecticut
$3.77M -$1.44M -87,500 -29%
Citadel Advisors
30
Citadel Advisors
Florida
$3.77M +$2.18M +132,658 +162%
Barclays
31
Barclays
United Kingdom
$3.26M +$168K +10,231 +6%
SC
32
Stempoint Capital
New York
$3.21M +$3.01M +183,102 New
EIM
33
Essex Investment Management
Massachusetts
$3.01M -$229K -13,963 -8%
Prudential Financial
34
Prudential Financial
New Jersey
$2.98M -$477K -29,030 -15%
Ameriprise
35
Ameriprise
Minnesota
$2.9M -$2.98M -181,582 -52%
Charles Schwab
36
Charles Schwab
California
$2.75M -$826K -50,242 -24%
LGM
37
Logos Global Management
California
$2.63M +$2.47M +150,000 New
Los Angeles Capital Management
38
Los Angeles Capital Management
California
$2.58M +$25.3K +1,540 +1%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$2.34M -$214K -13,015 -9%
LPC
40
Lion Point Capital
New York
$2.29M – – –
LTAS
41
Linden Thomas Advisory Services
North Carolina
$2.01M -$22K -1,341 -1%
ACM
42
ADAR1 Capital Management
Texas
$1.84M +$1.73M +105,000 New
UOC
43
UBS O'Connor
Illinois
$1.77M -$93.7K -5,701 -5%
HWAM
44
Hennion & Walsh Asset Management
New Jersey
$1.7M +$684K +41,594 +76%
Rafferty Asset Management
45
Rafferty Asset Management
New York
$1.68M -$711K -43,251 -31%
TC
46
Tejara Capital
United Kingdom
$1.67M +$989K +60,149 +172%
Qube Research & Technologies (QRT)
47
Qube Research & Technologies (QRT)
United Kingdom
$1.66M +$289K +17,562 +23%
Deutsche Bank
48
Deutsche Bank
Germany
$1.6M -$6.03K -367 -0.4%
HS
49
HighVista Strategies
Massachusetts
$1.56M +$1.46M +88,688 New
UBS Group
50
UBS Group
Switzerland
$1.5M +$371K +22,602 +36%
1
2
3 4 5

KNSA Hedge Fund Activity: Q4 2023 in Review

142 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2023, worth a combined $628M — up 3.7% from $606M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new KNSA positions and 20 closed out — a net gain of 9 holders — while 39 added to existing stakes and 57 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $27.9M. The largest seller was HHLR Advisors, exiting entirely with an estimated $12.1M sold.

  • 142 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2023, up from 134 in Q3 2023.
  • Funds reported $628M of Kiniksa Pharmaceuticals stock for Q4 2023, up 3.7% quarter-over-quarter.
  • 29 funds opened new Kiniksa Pharmaceuticals positions in Q4 2023 and 20 closed out, a net change of +9 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $27.9M added.
  • The largest Kiniksa Pharmaceuticals seller in Q4 2023 was HHLR Advisors, an estimated $12.1M sold.

Based on aggregated 13F filings for Q4 2023.